Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Roivant Sciences Ltd ROIV

Healthcare Biotechnology
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal... see more

Recent & Breaking News (NDAQ:ROIV)

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

GlobeNewswire 10 days ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

GlobeNewswire October 29, 2024

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

GlobeNewswire October 28, 2024

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

GlobeNewswire September 18, 2024

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

GlobeNewswire September 10, 2024

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

GlobeNewswire September 10, 2024

Roivant Provides Update on Graves' Disease Development Program

GlobeNewswire September 9, 2024

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

GlobeNewswire August 8, 2024

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

GlobeNewswire July 25, 2024

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

GlobeNewswire May 30, 2024

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

GlobeNewswire May 16, 2024

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

GlobeNewswire April 2, 2024

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

PR Newswire March 26, 2024

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

GlobeNewswire February 13, 2024

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

GlobeNewswire January 30, 2024

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

GlobeNewswire December 20, 2023

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

GlobeNewswire December 14, 2023

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

GlobeNewswire November 28, 2023

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

GlobeNewswire November 27, 2023

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

GlobeNewswire November 13, 2023